B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
